Indian CRO GVK Biosciences is working to get back in the good graces of European regulators after inspectors found evidence that its employees doctored clinical trial results.
Price caps on "essential drugs" in India have been a sore point with domestic as well as Big Pharma players. The industry was further enraged when an Indian agency in May assumed the authority to add other products to the 350 already restricted. But the government of Prime Minister Narendra Modi is reining in the National Pharmaceutical Pricing Authority (NPPA), suggesting he may have a less populous approach to the industry than his predecessor.
As promised, newcomer COO Christophe Weber is shaking things up at Takeda Pharmaceutical, with the Japanese company this week rolling out a revamped organizational structure that it hopes will make it the "best-in-class company in every aspect" of its business. And that includes vaccines.
Cheap Sovaldi is on the way, and it could very well be coming to an emerging market near you. Gilead has ironed out a licensing deal for the hep C wonder with 7 companies--including Mylan and Ranbaxy--and they'll bring low-cost copies to 91 developing countries.
Abbott Laboratories will invest $60 million in an intraocular lens manufacturing plant in Malaysia. The plant is expected to employ about 500 people and to be operational next year, producing 1 million sets of IOLs a year.
Blackberry is launching an ambitious project to integrate thousands of medical devices in India in order to detect illnesses earlier.
Turns out it's not just India and Egypt that will be getting price breaks on Gilead's hep C star, Sovaldi. The drugmaker is close to reaching an agreement with generics makers to bring low-cost versions of the $84,000 wonder drug to about 80 developing countries, according to EVP Gregg Alton.
Sweden's Recipharm in April issued additional shares, preparing itself for expansion. Now the midsized contract and development group is putting those plans into play, buying an Italian company for more than $160 million, getting new business in Italy and emerging markets, as well as new capabilities.
Global med tech companies could soon face mounting competition in China, as the country's top health authority is calling for a new set of initiatives to promote homegrown products and jumpstart the domestic industry.
Conspiring to keep distributors from working with generic drugmakers is a no-no in Brazil, and the country's antitrust regulator is fining Merck KGaA for allegedly doing just that. And while the move harkens back to a meeting that happened 5 years ago, it's reflective of actions taken more recently by regulators in the U.S. and EU.